| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*See the Appendix on page 449 for a complete list of the members of the Working Group on Peripheral Neuropathy.
Address correspondence and reprint requests to Dr. Jerry R. Mendell, Department of Neurology, 1654 Upham Drive, Columbus, OH 43210.
OBJECTIVE: To determine the efficacy of IV immunoglobulin (IVIg) given patients with untreated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
METHODS: A randomized, double-blind, multicenter, investigator-initiated study compared IVIg (Aventis Behring LLC, King of Prussia, PA) with placebo (5% albumin). On days 1, 2, and 21, IVIg (1 g/kg) or placebo was given. The primary outcome measure was the change in muscle strength from baseline to day 42, using the average muscle score (AMS). Secondary outcome measures included change from baseline AMS at days 10 and 21, the Hughes’ functional disability scale, forced vital capacity (FVC), and nerve conduction studies (NCS) of four motor nerves (median, ulnar, peroneal, and tibial).
RESULTS: The patients (n = 33) were randomized. Of these, 30 (14 women, 16 men, aged 54 ± 20 years, range 13 to 82) received IVIg and 23 were given placebo (12 women, 11 men, aged 50 ± 18 years, range 23 to 73). Baseline AMS values of the groups were similar (IVIg 7.06 ± 1.31 versus placebo 7.28 ± 1.18, p = 0.53). There were two dropouts in placebo group and one in the IVIg group. Mean AMS improved at day 42 comparing IVIg with placebo (0.63 versus -0.1, p = 0.006). Improved strength was seen by day 10. The placebo group lost strength over this same interval. In the IVIg, 11 subjects improved by the functional disability scale; none worsened. This differed (p = 0.019) from those in the placebo-treated group (two improved, two got worse, remainder unchanged). Forced vital capacity did not improve with IVIg treatment. IVIg improved ulnar motor distal latency (p = 0.005), tibial distal compound muscle amplitude (p = 0.003), and peroneal nerve conduction velocity (p = 0.03).
CONCLUSIONS: IVIg improves strength in patients with untreated CIDP by day 10 with continued benefit through day 42; more than one third improve by at least a functional grade on a disability scale. This study provides data supporting IVIg as the initial treatment for CIDP.
This article has been cited by other articles:
|
|
 |
|
  H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
 |
|
 I.S.J. Merkies, V. Bril, M. C. Dalakas, C. Deng, P. Donofrio, K. Hanna, H-P Hartung, R. A.C. Hughes, N. Latov, P. A. van Doorn, et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: The ICE Study Neurology, April 14, 2009; 72(15): 1337 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tackenberg, I. Jelcic, A. Baerenwaldt, W. H. Oertel, N. Sommer, F. Nimmerjahn, and J. D. Lunemann Impaired inhibitory Fc{gamma} receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy PNAS, March 24, 2009; 106(12): 4788 - 4792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]
|
|
|
|
 |
|
 A Hrobjartsson, E Forfang, M. Haahr, B Als-Nielsen, and S Brorson Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding Int. J. Epidemiol., June 1, 2007; 36(3): 654 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Odaka, M Tatsumoto, K Susuki, K Hirata, and N Yuki Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin J. Neurol. Neurosurg. Psychiatry, August 1, 2005; 76(8): 1115 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. H. Van Asseldonk, L. H. Van den Berg, S. Kalmijn, J. H. J. Wokke, and H. Franssen Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37{degrees}C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy Brain, April 1, 2005; 128(4): 880 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung Chronic Inflammatory Demyelinating Polyneuropathy N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356. [Full Text] [PDF]
|
|
|
|
 |
|
 P Vermersch, T Stojkovic, and J de Seze Mycophenolate mofetil and neurological diseases Lupus, March 1, 2005; 14(3_suppl): s42 - s45. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Lopate, A. Pestronk, and M. Al-Lozi Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone Arch Neurol, February 1, 2005; 62(2): 249 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vermersch, T. Stojkovic, and J. de Seze Mycophenolate mofetil and neurological diseases Lupus, January 1, 2005; 14(1_suppl): s42 - s45. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases JAMA, May 19, 2004; 291(19): 2367 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Ropper Current treatments for CIDP Neurology, April 22, 2003; 60(90083): S16 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Mendell and Z. Sahenk Painful Sensory Neuropathy N. Engl. J. Med., March 27, 2003; 348(13): 1243 - 1255. [Full Text] [PDF]
|
|
|
|
|
|
H. W. Sander and E. T. Hedley-Whyte Case 6-2003 - A Nine-Year-Old Girl with Progressive Weakness and Areflexia N. Engl. J. Med., February 20, 2003; 348(8): 735 - 743. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Dalakas Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies Neurology, December 24, 2002; 59(90126): S13 - 21. [Abstract] [Full Text]
|
|
|
|
|
|
C. L. Koski Therapy of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S22 - 27. [Abstract] [Full Text]
|
|
|
|
|
|
T. H. Brannagan III Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S33 - 40. [Abstract] [Full Text]
|
|
|
|
|
|
K. R. Sharma, J. Cross, D. R. Ayyar, A. Martinez-Arizala, and W. G. Bradley Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy Arch Neurol, May 1, 2002; 59(5): 751 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Gorson, A. H. Ropper, D. H. Weinberg, and R. Weinstein Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy Arch Neurol, May 1, 2002; 59(5): 766 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Benatar and J. R. Mendell Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy Neurology, September 11, 2001; 57(5): 938 - 938. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
